Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 16, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors

AUSTIN, Texas, July 16, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
June 29, 2018 16:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AUSTIN, Texas, June 29, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
May 15, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present at UBS Global Healthcare Conference

AUSTIN, Texas, May 15, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
May 08, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results

AUSTIN, Texas, May 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
April 18, 2018 22:50 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Prices Public Offering of Common Stock

AUSTIN, Texas, April 18, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
April 17, 2018 16:01 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock

AUSTIN, Texas, April 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
April 12, 2018 07:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics Meeting

Clinical Outcome Assessment Tools Detected and Quantified Baseline Abnormalities Clinically Relevant Improvement Seen in Multiple Neuromotor Tests Company to Host Clinical Update Conference Call...
April 05, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting

AUSTIN, Texas, April 05, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
April 03, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting

AUSTIN, Texas, April 03, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
April 02, 2018 08:00 ET | Source: Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials

AUSTIN, Texas, April 02, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right